Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.64 |
| ▸ | CYSLTR1 | Q9Y271 | 13/20 | 0.59 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.59 |
| ▸ | CYSLTR2 | Q9NS75 | 9/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9053379 | 0.84 | ALOX5 (0.72) | ALOX5CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL9053241 | 0.81 | CYSLTR1 (0.73) | ALOX5CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL10692276 | 0.78 | ALOX5 (1.00) | ALOX5CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL10696181 | 0.78 | ALOX5 (0.69) | ALOX5CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL7808132 | 0.76 | ALOX5 (0.63) | ALOX5CYSLTR1 | |
| SCHEMBL7458734 | 0.76 | CYSLTR1 (0.68) | ALOX5CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL4848317 | 0.75 | CYSLTR1 (1.00) | ALOX5CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL8321128 | 0.75 | CYSLTR1 (0.76) | ALOX5CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL30443879 | 0.75 | CYSLTR1 (1.00) | ALOX5CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL14021757 | 0.75 | CYSLTR1 (0.82) | ALOX5CYSLTR1GPBAR1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297133-A1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | Envivo Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009158393-A1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |